PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 74.72

Change

-0.51 (-0.68)%

Market Cap

USD 8.99B

Volume

0.84M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.53 (-0.30%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.46 (-1.98%)

USD 76.39B
ARGX argenx NV ADR

-3.01 (-0.49%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

-8.81 (-3.48%)

USD 31.94B
ONC BeiGene, Ltd.

-3.69 (-1.39%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.39 (+1.18%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.30 (-1.49%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-8.82 (-2.73%)

USD 14.37B
INCY Incyte Corporation

-2.01 (-3.24%)

USD 14.22B
MRNA Moderna Inc

-0.90 (-2.59%)

USD 13.74B

ETFs Containing PCVX

HVAX:CA 4.86 % 0.00 %

N/A

N/A
WELL:PA HAN-GINS Indxx Healthcare.. 4.77 % 0.00 %

-0.01 (-0.53%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.77 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 4.57 % 0.00 %

-0.26 (-0.53%)

USD 0.02B
CURE:AU ETFS S&P Biotech ETF 2.28 % 0.00 %

+0.39 (+-0.53%)

USD 0.04B
VRTGX Vanguard Russell 2000 Gro.. 0.76 % 0.00 %

-4.40 (-0.53%)

USD 1.19B
R2US:PA SSgA SPDR ETFs Europe II .. 0.40 % 0.00 %

-0.06 (-0.53%)

USD 4.74B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.40 % 0.00 %

N/A

USD 2.91B
R2US:SW SPDR® Russell 2000 US Sm.. 0.40 % 0.00 %

-0.27 (-0.53%)

USD 4.92B
XRS2:F Xtrackers (IE) Public Lim.. 0.40 % 0.00 %

-3.15 (-0.53%)

USD 1.19B
XRS2:SW Xtrackers Russell 2000 UC.. 0.40 % 0.00 %

+1.50 (+-0.53%)

USD 2.15B
RSSL Global X Funds 0.39 % 0.00 %

-0.75 (-0.53%)

USD 1.55B
VRTIX Vanguard Russell 2000 Ind.. 0.39 % 0.00 %

-2.82 (-0.53%)

USD 10.02B
ITWO Proshares Russell 2000 Hi.. 0.35 % 0.00 %

-0.19 (-0.53%)

USD 0.05B
UWM ProShares Ultra Russell20.. 0.30 % 0.95 %

-0.54 (-0.53%)

USD 0.32B
HDG ProShares Hedge Replicati.. 0.05 % 0.95 %

-0.11 (-0.53%)

USD 0.02B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

-2.24 (-0.53%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-3.46 (-0.53%)

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

-0.91 (-0.53%)

USD 0.41B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

-2.43 (-0.53%)

USD 1.05B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

-0.66 (-0.53%)

USD 11.80B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.09 (-0.53%)

USD 4.81B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.05 (-0.53%)

USD 4.74B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-35.50 (-0.53%)

USD 2.15B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-0.39 (-0.53%)

USD 2.11B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-0.65 (-0.53%)

N/A
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.17 (-0.53%)

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.07 (-0.53%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.72% 60% D- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.72% 60% D- 42% F
Trailing 12 Months  
Capital Gain 10.53% 81% B- 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.53% 81% B- 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 40.06% 75% C 85% B
Dividend Return 40.06% 75% C 85% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.20% 61% D- 36% F
Risk Adjusted Return 73.91% 98% N/A 89% A-
Market Capitalization 8.99B 97% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector